# A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents

> **NCT00355524** · PHASE2 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 80 (actual)

## Conditions studied

- HIV-1
- HIV Infections

## Interventions

- **DRUG:** TMC114
- **DRUG:** Ritonavir

## Key facts

- **NCT ID:** NCT00355524
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2007-08
- **Final completion:** 2011-03
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2013-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00355524

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00355524, "A Phase 2 Study to Evaluate Pharmacokinetics, Safety and Efficacy of TMC114/Ritonavir (Rtv) in Human Immunodeficiency Virus (HIV)-1 Infected Children and Adolescents". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00355524. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*